Aizhan Akhayeva

Aizhan Akhayeva

Auto-generated profile, based on publicly available information

Aizhan Akhayeva

Department of Cell Technologies and Transplantation, JSC “National Scientific Medical Center”, Astana, Kazakhstan

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 December 2025 in Journal of Clinical Medicine of Kazakhstan
Verified
Journal Article
Open access
PDF file
ABAbay Baigenzhin
Abay Baigenzhin
ECElmira Chuvakova
Elmira Chuvakova
AZAigerim Zhakupova
Aigerim Zhakupova
AAAizhan Akhayeva
Aizhan Akhayeva
AGAnastasia Ganina
Anastasia Ganina
During the last decade, clinical application of extracellular vesicles (EVs) is of growing interest. Despite the progress in exploring the therapeutic potential of EVs, e.g. as disease markers or the carriers for therapeutic substances, it is important to identify proper storage conditions – this issue is indeed challenging. A subtype of EVs known as exosomes is of great importance in the therapeutic applications because they participate in the regulation of intercellular communication. Currently, exosomes are considered as a promising tool in the regenerative medicine. The therapeutic potential of exosomes and other subtypes of EVs, especially for their using in immunomodulation and drug delivery, dictates great attention to the methods for their storage, in particular for a long periods of time. Lyophilization is one of the best such methods designed to preserve cell-free EV-based products. In our mini-review, we discuss the main methods developed for stabilizing cell-free products and getting stable solid forms of EVs that are capable for long-term storage. We also point out that the methods need to be following both the ease of transportation and the retaining the functionally important properties for in vivo applications. The development of optimal protocols for storing the EVs are therefore crucially important for warranting that structural and functional integrity of EVs, exosomes in particular, are maintained intact or at least modified as less as possible. For comprehensiveness of our review, we refer to original studies which investigated how the storage temperature and freezing methods may affect stability of the final EV product. We summarize advances in the area of freeze-drying EVs (exosomes), the selection of optimal process parameters and lyoprotectants, the interplay between lyophilization parameters and specific functional properties of exosomes, and the preservation of their biological activity after reconstitution before application in vivo.

8 July 2025 in Journal of Clinical Medicine of Kazakhstan
Verified
Journal Article
Open access
MLMeruert Latipbayeva
Meruert Latipbayeva
MAManarbek Askarov
Manarbek Askarov
TSTelman Seisembekov
Telman Seisembekov
DZDinara Zakarina
Dinara Zakarina
ABAbay Baigenzhin
Abay Baigenzhin
GKGulzi Kusayynkhan
Gulzi Kusayynkhan
Background: Dilated cardiomyopathy (DCM) is one of the main causes of heart failure induction all over the world. In non-clinical trial many authors have demonstrated safety and effectiveness of autologous mesenchymal stem cells (MSCs). However, effectiveness of autologous MSCs in DCM with reduced ejection fraction (HFrEF) (≤40%) has been studied insufficiently. Objective: To evaluate effectiveness of autologous cell therapy in patients with dilated cardiomyopathy and reduced left ventricular ejection fraction. Methods: This single center randomized clinical study included 61 patients with DCM, class III-IV of heart failure according to New York Heart Association (NYHA), with HFrEF (≤40%) who made 2 visits every 3 months. Patients included in the study were randomized into two groups: the main group (32 patients) and the control group (29 patients). Patients of the main group received standard optimal medical therapy (OMT) and cell therapy, and patients of the second group received OMT. Data were analyzed using SPSS Statistica 10 and GraphPad Prism 7. Results: The median patient age in control group was 57.0±12.0 and in the main group was 47.0±10.4 years. On average ~2/3 of the total number of patients were male in both groups. Disease duration in control group was 4.9 ± 3.1, and in main group was 4.8 ± 2.8. Сomorbidities: type 2 diabetes mellitus (DM), arterial hypertension (AH) and cardiac arrhythmias (CA) did not differ between groups amounting to 17 to 44% of all patients. After 12 months of observation main group showed significant improvements associated with cell therapy: based on the results of laboratory test: statistically significant decrease in the level of eosinophils, normalization of coagulogram parameters, decrease in urea and increase in blood calcium, furthermore, there was a notable increase in anti-inflammatory cytokines CD73+ and IL-4, alongside reduction in pro-inflammatory CD8+ levels and brain natriuretic peptide (NT-proBNP). Echocardiographic (ECHO) data revealed significant increase in LVEF from 26.1 ± 8.4% to 37.6 ± 7.6% (p<0.0001) and reduction in end-systolic volume (ESV) from 146 ± 54 to 113 ± 42 p=0.0496) in the main group, whereas no such changes were observed in the control group. Conclusion: Combined therapy, including OMT and cell therapy, resulted in improved left ventricular function, reduced cardiac chamber dimensions (according to echocardiographic data), decreased pro-BNP levels, and improved routine laboratory parameters. However, these findings require confirmation in large-scale, multicenter randomized clinical trial Keywords: heart failure, dilated cardiomyopathy, cell therapy, mesenchymal stem cells.

27 February 2026 in Astana Medical Journal
Verified
Journal Article
Closed access
PDF file
AOAzamat Omargali
Azamat Omargali
TYTanzira Yedilbayeva
Tanzira Yedilbayeva
AGAnastasia Ganina
Anastasia Ganina
AAAizhan Akhayeva
Aizhan Akhayeva
The purpose of this review is to provide an updated overview of the potential use of mesenchymal stem cells (MSCs) in regenerative medicine. MSCs can be isolated from various tissues, and their biological properties largely depend on their source. Bone marrow-derived MSCs remain the most studied and widely used; however, their use is limited by the invasive nature of their collection, low cell yield, and age-related decline in regenerative potential. The human placenta offers an alternative source of MSCs for drug research and development due to its high availability, the ability to obtain large numbers of cells, and low immunogenicity. This review aims to summarize current literature data on the regenerative properties of human bone marrow and placental mesenchymal stem cells and to compare their potential for use in regenerative medicine. Keywords: mesenchymal stem cells, regenerative cell therapy, bone marrow-derived mesenchymal stem cells, placental mesenchymal stem cells.